RxDoctor Payments Data

Holly Williams, NP

Adult Health · Carmel, INNPI 1225301831

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.2% of the total across 112 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations.

$3,630in general payments, 2019–2025

Across 112 payments — averaging $32.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$702
  • Abbott$606
  • Boston Scientific$506
  • Alnylam Pharmaceuticals Inc.$292
  • Amgen$284
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$272
  • plus $968 from 14 others

What the payments were for

  • Food & beverage$3,45695%
  • Education$1745%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,630 in reported general payments places this provider in the 85th percentile of 391 adult health providers in Indiana.

See all adult health providers in Indiana

Medicare billing

Part B allowed, 2024
$2,067
Medicare patients
24
Services billed
25

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban47$34,020
BrilintaTicagrelor30$12,335
EntrestoSacubitril/Valsartan17$10,304
JardianceEmpagliflozin14$9,220
Metoprolol Succinate55$671
ClopidogrelClopidogrel Bisulfate58$425
Atorvastatin Calcium35$217
Rosuvastatin Calcium11$211
Diltiazem 24hr Er (Cd)Diltiazem Hcl12$189
Amiodarone Hcl16$182
Furosemide36$95
Isosorbide Mononitrate ErIsosorbide Mononitrate12$52
Spironolactone11$28
Amlodipine Besylate11$18

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$67$34,02047 claims
AstraZenecaBrilinta$702$12,33530 claims
NovartisEntresto$70$10,30417 claims
Boehringer IngelheimJardiance$125$9,22014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 391 adult health providers in Indiana.

Other adult health in Carmel

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →